组蛋白去乙酰化酶抑制剂的抗肿瘤作用

doi:10.3760/cma.j.issn.1673-422X.2017.10.008

摘要/Abstract

摘要： 组蛋白去乙酰化酶（HDAC）是一类蛋白酶，对染色体的结构修饰和基因表达调控发挥着重要的作用。其在癌细胞中的过量表达引起乙酰化失衡，与肿瘤的发生有着密切联系。随着表观遗传学研究的深入，组蛋白去乙酰化酶抑制剂（HDACi）作为抗肿瘤药物，其高效性和低毒性得到了广泛的认可，相信会为肿瘤的治疗带来更多的突破。

关键词: 后成说, 遗传, 肿瘤, 组蛋白去乙酰化酶抑制剂

Abstract: Histone deacetylase (HDAC) is a kind of protease, which plays an important role in the structural modification of chromosomes and the regulation of gene expression. Its excessive expression in cancer cells causes acetylation imbalance, which is closely related to the occurrence of tumor. The high efficiency and low toxicity of histone deacetylase inhibitor (HDACi) has been widely recognized as antitumor drug with the deepening of the study in epigenetics. It is expected to bring more breakthroughs in the treatment of tumor.

Key words: Epigenesis, genetic, Neoplasms, Histone deacetylase inhibitors

肖洒,李玲,张明智. 组蛋白去乙酰化酶抑制剂的抗肿瘤作用[J]. 国际肿瘤学杂志, 2017, 44(10): 754-757.

Xiao Sa, Li Ling, Zhang Mingzhi. Antitumor effect of histone deacetylase inhibitors[J]. Journal of International Oncology, 2017, 44(10): 754-757.

参考文献

［1］ Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis［J］. J Mol Biol, 2004, 338(1): 1731. DOI: 10.1016/j.jmb.2004.02.006. ［2］ Deacetylases H. Characterization of the classical HDAC family［J］. Biochem J, 2003, 370(Pt 3): 737749. ［3］ Lakshmaiah KC, Jacob LA, Aparna S, et al. Epigenetic therapy of cancer with histone deacetylase inhibitors［J］. J Cancer Res Ther, 2014, 10(3): 469478. DOI: 10.4103/09731482.137937. ［4］ Koeneke E, Witt O, Oehme I. HDAC family members intertwined in the regulation of autophagy: a druggable vulnerability in aggressive tumor entities［J］. Cells, 2015, 4(2): 135168. DOI: 10.3390/cells4020135. ［5］ Olsen EA, Kim YH, Kuzel TM, et al. Phase Ⅱb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous Tcell lymphoma［J］. J Clin Oncol, 2007, 25(21): 31093115. DOI: 10.1200/JCO.2006.10.2434. ［6］ Damaskos C, Karatzas T, Nikolidakis L, et al. Inhibitors: current evidence for therapeutic activities in pancreatic cancer［J］. Anticancer Res, 2015, 35(6): 31293135. ［7］ Takashina T, Kinoshita I, Kikuchi J, et al. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for nonsmallcell lung cancer cells［J］. Cancer Sci, 2016, 107(7): 955962. DOI: 10.1111/cas.12957. ［8］ Shin DY, Kim SJ, Yoon DH, et al. Results of a phase Ⅱ study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis［J］. Cancer Chemother Pharmacol, 2016, 77(4): 865873. DOI: 10.1007/s002800163005y. ［9］ Pili R, Liu G, Chintala S, et al. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clearcell renal cell carcinoma: a multicentre, singlearm phase Ⅰ/Ⅱ clinical trial［J］. Br J Cancer, 2017, 116(7): 874883. DOI: 10.1038/bjc.2017.33. ［10］ Pera B, Tang T, Marullo R, et al. Combinatorial epigenetic therapy in diffuse large B cell lymphoma preclinical models and patients［J］. Clin Epigenetics, 2016, 8: 79. DOI: 10.1186/s131480160245y. ［11］ Holkova B, Kmieciak M, Bose P, et al. Phase 1 trial of carfilzomib (PR171) in combination with vorinostat (SAHA) in patients with relapsed or refractory Bcell lymphomas［J］. Leuk Lymphoma, 2016, 57(3): 635643. DOI: 10.3109/10428194.2015.1075019. ［12］ Angelika Ihle M, MerkelbachBruse S, Hartmann W, et al. HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat［J］. J Pathol Clin Res, 2016, 2(2): 5971. DOI: 10.1002/cjp2.35. ［13］ Gu R, Liu T, Zhu X, et al. Development and validation of a sensitive HPLCMS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application［J］. J Chromatogr B Analyt Technol Biomed Life Sci, 2015, 1000: 181186. DOI: 10.1016/j.jchromb.2015.07.001. ［14］ Hu X, Wang L, Lin L, et al. A phase Ⅰ trial of an oral subtypeselective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced nonsmall cell lung cancer［J］. Chin J Cancer Res, 2016, 28(4): 444451. DOI: 10.21147/j.issn.10009604.2016.04.08. ［15］ Zhao S, Guo J, Zhao Y, et al. Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling［J］. Am J Transl Res, 2016, 8(7): 31693178. ［16］ Liu L, Qiu S, Liu Y, et al. Chidamide and 5flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice［J］. Neoplasma, 2016, 63(2): 193200. DOI: 10.4149/203_150422N214. ［17］ Lee HZ, Kwitkowski VE, Del Valle PL, et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral Tcell lymphoma［J］. Clin Cancer Res, 2015, 21(12): 26662670. DOI: 10.1158/10780432.CCR143119. ［18］ O′Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral Tcell lymphoma: results of the pivotal phase Ⅱ BELIEF (CLN19) study. J Clin Oncol, 2015, 33(23): 24922499. DOI: 10.1200/JCO.2014.59.2782. ［19］ O′connor OA, Zullo K, Marchi E, et al. Targeting epigenetic operations with HDAC inhibitor and hypomethylating drugs in combination exhibit synergy in preclinical and clinical experiences in drug resistant Tcell lymphoma (TCL): a translational focus on doublet development［J］. Blood, 2015, 126(23): 109120. ［20］ Havas AP, Rodrigues KB, Bhakta A, et al. Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma［J］. Cancer Biol Ther, 2016, 17(12): 12401252. DOI: 10.1080/15384047.2016.1250046. ［21］ To KK, Tong WS, Fu LW. Reversal of Platinum drug resistance by the histone deacetylase inhibitor belinostat［J］. Lung Cancer, 2017, 103: 5865. DOI: 10.1016/j.lungcan.2016.11.019. ［22］ SanMiguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, doubleblind phase 3 trial［J］. Lancet Oncol, 2014, 15(11): 11951206. DOI: 10.1016/S14702045(14)704401. ［23］ Richardson PG, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment［J］. Blood, 2016, 127(6): 713721. DOI: 10.1182/blood201509665018. ［24］ Shi W, Palmer JD, WernerWasik M, et al. Phase Ⅰ trial of panobinostat and fractionated stereotactic reirradiation therapy for recurrent high grade gliomas［J］. J Neurooncol, 2016, 127(3): 535539. DOI: 10.1007/s1106001620593. ［25］ Tan WW, Allred JB, MorenoAspitia A, et al. Phase Ⅰ study of panobinostat (LBH589) and letrozole in postmenopausal metastatic breast cancer patients［J］. Clin Breast Cancer, 2016, 16(2): 8286. DOI: 10.1016/j.clbc.2015.11.003. ［26］ Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, openlabel, phase Ⅱ study of romidepsin in relapsed or refractory peripheral Tcell lymphoma after prior systemic therapy［J］. J Clin Oncol, 2012, 30(6): 631636. DOI: 10.1200/JCO.2011.37.4223. ［27］ Foss F, Horwitz S, Pro B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial［J］. J Hematol Oncol, 2016, 9(1): 22. DOI: 10.1186/s1304501602438. ［28］ Pellegrini C, Dodero A, Chiappella A, et al. A phase Ⅱ study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral Tcell lymphoma patients［J］. J Hematol Oncol, 2016, 9(1): 38. DOI: 10.1186/s1304501602661.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.